



## **Summary of risk management plan for AJOVY® (fremanezumab)**

**Teva Pharma AG  
Kirschgartenstrasse 14  
4010 Basel**

Document Version: 1.0

Document Date: 22.02.2024

Based on EU RMP Version: 5.0

### **Disclaimer**

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risk as well as to prevent or minimize them.

The RMP summary of AJOVY® is a concise document and does not claim to be exhaustive.

As the RMP is an international document, the summary might differ from the "Arzneimittelinformation / Information sur le médicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization.

Please note that the reference document which is valid and relevant for the effective and safe use of AJOVY® in Switzerland is the "Arzneimittelinformation / Information sur le médicament" (see [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch)) approved and authorized by Swissmedic. Teva Pharma AG is fully responsible for the accuracy and correctness of the content of the published summary RMP of AJOVY®.

## **Summary of Risk Management Plan for AJOVY (fremanezumab)**

This is a summary of the risk management plan (RMP) for AJOVY (herein after also referred to as fremanezumab). The RMP details important risks of AJOVY, how these risks can be minimised, and how more information will be obtained about AJOVY's risks and uncertainties (missing information).

AJOVY's Summary of Product Characteristics (SmPC) and its Package Leaflet (PL) give essential information to healthcare professionals and patients on how AJOVY should be used.

This summary of the RMP for AJOVY should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of AJOVY's RMP.

### **I. The Medicine and What It is used for**

AJOVY is authorised for prophylaxis of migraine in adults who have at least 4 migraine days per month (see SmPC for the full indication). It contains fremanezumab as the active substance and it is given by subcutaneous injection.

Further information about the evaluation of AJOVY's benefits can be found in AJOVY's Swiss-SmPC: <https://www.swissmedicinfo.ch/>

### **II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks**

Important risks of AJOVY, together with measures to minimise such risks and the proposed studies for learning more about AJOVY's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including Periodic Safety Updated Report (PSUR) assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of AJOVY is not yet available, it is listed under 'missing information' below.

#### **II.A List of Important Risks and Missing Information**

Important risks of AJOVY are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of AJOVY. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

**Table 1: Summary of Safety Concerns**

<b>List of important risks and missing information</b>	
<b>Important identified risks</b>	<ul style="list-style-type: none"><li>• None</li></ul>
<b>Important potential risks</b>	<ul style="list-style-type: none"><li>• Unfavourable cardiovascular outcomes in patients with pre-existing myocardial infarction, cerebrovascular accident, transient ischemic attack, angina unstable, and hypertension</li></ul>
<b>Missing information</b>	<ul style="list-style-type: none"><li>• Long-term safety</li><li>• Use in pregnant women (including those at risk of pre-eclampsia)</li></ul>

## II.B Summary of Important Risks

**Table 2: Summary of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern**

<b>Important Identified Risks: None</b>	
<b>Important Potential Risk: Unfavourable cardiovascular outcomes in patients with pre-existing myocardial infarction, cerebrovascular accident, transient ischemic attack, angina unstable, and hypertension</b>	
Evidence for linking the risk to the medicine	<p>Due to its mechanism of action CGRP inhibitors are considered as having a theoretical potential to increase the risk for hypertension/hypertensive crisis, cardiovascular and cerebrovascular disease, as well as for peripheral arterial disorder. Patients with a history of significant cardiovascular and cerebrovascular disease, as well as patients with a history of thromboembolic events had been excluded from trial participation. Due to the clinical trial exclusion criteria limited data are available in this patient group. Based on the data on cardiovascular safety in clinical studies there is no clear trend or signal that suggests an increased risk of cardiac disorders in patients with fremanezumab. In clinical studies the safety profile of fremanezumab was comparable across age groups without specific safety signals for patients with cardiovascular risk factors.</p>
Risk factors and risk groups	Unknown
Risk minimisation measures	<p><u>Routine risk minimisation measures</u></p> <ul style="list-style-type: none"> <li>• SmPC sections 4.4</li> <li>• PL section 2</li> <li>• Medicinal product subject to restricted medical prescription</li> </ul>
Additional pharmacovigilance activities	<ul style="list-style-type: none"> <li>• A Long-Term Observational, Retrospective Cohort Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice in the United States and Europe</li> </ul>
<b>Missing information: Long-term safety</b>	
Risk minimisation measures	<p><u>Routine risk minimisation measures</u></p> <ul style="list-style-type: none"> <li>• Medicinal product subject to restricted medical prescription</li> </ul>
Additional pharmacovigilance activities	<ul style="list-style-type: none"> <li>• A Long-Term Observational, Retrospective Cohort Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice in the United States and Europe</li> </ul>
<b>Missing information: Use in pregnant women (including those at risk of pre-eclampsia)</b>	
Risk minimisation measures	<p><u>Routine risk minimisation measures</u></p> <ul style="list-style-type: none"> <li>• SmPC section 4.6</li> <li>• PL section 2</li> <li>• Medicinal product subject to restricted medical prescription</li> </ul>
Additional pharmacovigilance activities	<ul style="list-style-type: none"> <li>• Assessment of pregnancy outcomes in patients treated with fremanezumab: Pregnancy Registry</li> <li>• Assessment of pregnancy outcomes in patients treated with fremanezumab: Pregnancy Database Study</li> </ul>

AJOVY ® (Fremanezumab) 225mg solution for injection in a prefilled syringe, in a prefilled pen

## II.C Post-Authorisation Development Plan

### II.C.1 Studies Which Are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of fremanezumab.

### II.C.2 Other Studies in Post-Authorisation Development Plan

Study name	Purpose of the study
Assessment of pregnancy outcomes in patients treated with fremanezumab: Pregnancy Registry	The overall aim of this study is to assess major adverse maternal, fetal, and infant outcomes during pregnancy and up to 1 year after birth by comparing women exposed to AJOVY before or during pregnancy to comparison groups unexposed to AJOVY.
Assessment of pregnancy outcomes in patients treated with fremanezumab: Pregnancy Database Study	The objective of this study is to assess the risk of major congenital malformations, spontaneous abortions, stillbirths, preeclampsia, eclampsia, preterm delivery, low birth weight, and small-for-gestational age births in women exposed to AJOVY during pregnancy compared to comparison populations unexposed to AJOVY.
A Long-Term Observational, Retrospective Cohort Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice in the United States and Europe	The study aims to evaluate the incidence of new onset hypertension and the worsening of preexisting hypertension in patients treated with fremanezumab in addition to the long-term safety of fremanezumab in both cardiovascular compromised and cardiovascular uncompromised patients in comparison to migraine patients treated with other prophylactic migraine medication.